Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 7/20 | 0.50 |
| ▸ | PPARD | Q03181 | 7/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990241 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3990463 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3986008 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3987683 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3992011 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3993682 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3987319 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3987265 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL379850 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL3988381 | 1.00 | KMT2A (0.56) | KMT2AMAPTCES2CES1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330667-A1 | TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME | LUMOSA THERAPEUTICS CO., LTD. (TW) | 2021-10-28 | — | — | US | disclosed |
| EP-2303265-B1 | STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE | GLENMARK PHARMACEUTICALS LTD (IN) | 2014-12-10 | — | — | EP | disclosed |
| US-20110105448-A1 | Stable Topical Formulation Comprising Voriconazole | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2011-05-05 | — | — | US | disclosed |
| EP-2303265-A2 | STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE | Glenmark Pharmaceuticals Limited (IN) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010084505-A2 | STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2010-07-29 | — | — | WO | disclosed |
| US-7537906-B2 | Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone | Nomura, Nobuhiko (JP) | 2009-05-26 | — | — | US | disclosed |
| EP-1879593-A2 | LOW DOSE ADMINISTRATION OF A TOPICAL COMPOSITION | MacroChem Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1865896-A1 | ENHANCEMENT OF MACROLIDE PENETRATION THROUGH HUMAN SKIN | MacroChem Corporation (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | MACRO CHEM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070190019-A1 | Compositions and methods for topical administration | MACROCHEM CORPORATION | 2007-08-16 | — | — | US | disclosed |
| EP-0971705-A4 | HORMONE REPLACEMENT THERAPY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN | MACROCHEM CORP (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1014942-A1 | NON-STEROIDAL ANTIINFLAMMATORY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN | MacroChem Corporation (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0983037-A4 | ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME | MACROCHEM CORP (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0983037-A1 | ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME | MacroChem Corporation (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0971705-A1 | HORMONE REPLACEMENT THERAPY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN | MacroChem Corporation (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5976566-A | INCLUDING IN THE FORMULATION 2-HYDROCARBYL-1,3-DIOXOLANE, 1,3-DIOXANE OR AN ACETAL, AS SKIN PENETRATION ENHANCING COMPOUND. | MACROCHEM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5968919-A | CONTAINING PENETRATION ENHANCER OF (HYDROCARBYL-SUBSTITUTED) 1,3-DIOXOLANE, 1,3-DIOXANE OR ACETAL | MACROCHEM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1999039680-A1 | ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME | MACROCHEM CORPORATION (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999020257-A1 | HORMONE REPLACEMENT THERAPY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN | MACROCHEM CORPORATION (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999009954-A1 | NON-STEROIDAL ANTIINFLAMMATORY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN | MACROCHEM CORPORATION (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | CYP8B1, NR1H3, NR1H2 | KMT2A 4753/4885MAPT 3668/4885CES2 440/4885 |
| US-20110105448-A1 | Stable Topical Formulation Comprising Voriconazole | ERG28, CYP51A1, PIK3C3 | KMT2A 3269/4885MAPT 901/4885CES2 4208/4885 |
| US-20070190019-A1 | Compositions and methods for topical administration | DSG1, CUTA, KRT18 | KMT2A 3494/4885MAPT 229/4885CES2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.